The present invention is directed to compounds that inhibit Usp14, compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.

The present invention is directed to compounds that inhibit Usp14, compositions thereof, and methods for the treatment of a condition associated with a dysfunction in proteostasis.

The present disclosure relates generally to inhibitors of mycobacterial membrane protein MmpL3, compositions comprising the inhibitors, and methods of preparation and use thereof.

Compounds, compositions, and methods are provided for dual partial agonism of serotonin 5-HTS and 5-HTIA receptors. The enantiomerically pure 5-phenyl-2-aminotetralin (5-PAT) compounds can be used to treat or prevent substance use disorder, opioid use disorder, addiction, anxiety, psychosis, depression, autism spectrum disorder, fragile X syndrome, neurological disorders, neuropsychiatric disorders, repetitive behaviors, movement disorders, compulsions, tics, pain disorders, vasospastic disorders, migraine headache, seizures, epilepsy, social anxiety, addiction withdrawal, drug withdrawal, drug abuse, alcoholism, eating disorders, general inflammation disorders, miosis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, and gastrointestinal disorders.

Compounds, compositions, and methods are provided for dual partial agonism of serotonin 5-HTS and 5-HTIA receptors. The enantiomerically pure 5-phenyl-2-aminotetralin (5-PAT) compounds can be used to treat or prevent substance use disorder, opioid use disorder, addiction, anxiety, psychosis, depression, autism spectrum disorder, fragile X syndrome, neurological disorders, neuropsychiatric disorders, repetitive behaviors, movement disorders, compulsions, tics, pain disorders, vasospastic disorders, migraine headache, seizures, epilepsy, social anxiety, addiction withdrawal, drug withdrawal, drug abuse, alcoholism, eating disorders, general inflammation disorders, miosis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, and gastrointestinal disorders.

A cyclopropylamine compound as a lysine-specific demethylase 1 (LSD1) inhibitor. Particularly, the present invention relates to a compound represented by formula (I) and a pharmaceutically acceptable salt thereof. The present invention also provides an application of the same in preparing a drug for treating an LSD1-related disease. ##STR00001##

A cyclopropylamine compound as a lysine-specific demethylase 1 (LSD1) inhibitor. Particularly, the present invention relates to a compound represented by formula (I) and a pharmaceutically acceptable salt thereof. The present invention also provides an application of the same in preparing a drug for treating an LSD1-related disease. ##STR00001##

Provided herein are enantioselective organocatalytic methods for preparing chiral tetraaryl methanes.

A compound that is fluidized by light irradiation and reversibly non-fluidized and is represented by the following general formula (1):

##STR00001##

In the general formula (1), Ar.sub.1 and Ar.sub.2 each independently represent an aromatic hydrocarbon group optionally having a substituent or an aromatic heterocyclic group optionally having a substituent, and Y, Z.sub.1, and Z.sub.2 each independently represent a hydrogen atom or a lower alkyl group.

A compound that is fluidized by light irradiation and reversibly non-fluidized and is represented by the following general formula (1):

##STR00001##

In the general formula (1), Ar.sub.1 and Ar.sub.2 each independently represent an aromatic hydrocarbon group optionally having a substituent or an aromatic heterocyclic group optionally having a substituent, and Y, Z.sub.1, and Z.sub.2 each independently represent a hydrogen atom or a lower alkyl group.